BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Han X, Wu Y, Yang Q, Cao G. Peroxisome proliferator-activated receptors in the pathogenesis and therapies of liver fibrosis. Pharmacol Ther 2021;222:107791. [PMID: 33321113 DOI: 10.1016/j.pharmthera.2020.107791] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Li J, Guo C, Wu J. The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis. Drug Des Devel Ther 2021;15:2619-28. [PMID: 34168433 DOI: 10.2147/DDDT.S310163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Cui ZY, Han X, Jiang YC, Dou JY, Yao KC, Hu ZH, Yuan MH, Bao XX, Zhou MJ, Liu Y, Lian LH, Zhang X, Nan JX, Wu YL. Allium victorialis L. Extracts Promote Activity of FXR to Ameliorate Alcoholic Liver Disease: Targeting Liver Lipid Deposition and Inflammation. Front Pharmacol 2021;12:738689. [PMID: 34690775 DOI: 10.3389/fphar.2021.738689] [Reference Citation Analysis]
3 Zhou JP, Yang XN, Song Y, Zhou F, Liu JJ, Hu YQ, Chen LG. Rosiglitazone alleviates lipopolysaccharide-induced inflammation in RAW264.7 cells via inhibition of NF-κB and in a PPARγ-dependent manner. Exp Ther Med 2021;22:743. [PMID: 34055059 DOI: 10.3892/etm.2021.10175] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Tai Y, Zhao C, Lan T, Zhang L, Xiao Y, Tong H, Liu R, Tang C, Gao J. Integrated Analysis of Hepatic miRNA and mRNA Expression Profiles in the Spontaneous Reversal Process of Liver Fibrosis. Front Genet 2021;12:706341. [PMID: 34367261 DOI: 10.3389/fgene.2021.706341] [Reference Citation Analysis]
5 Qu W, Ma T, Cai J, Zhang X, Zhang P, She Z, Wan F, Li H. Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies. Front Med (Lausanne) 2021;8:761538. [PMID: 34746195 DOI: 10.3389/fmed.2021.761538] [Reference Citation Analysis]
6 Wang S, Tang C, Zhao H, Shen P, Lin C, Zhu Y, Han D. Network Pharmacological Analysis and Experimental Validation of the Mechanisms of Action of Si-Ni-San Against Liver Fibrosis. Front Pharmacol 2021;12:656115. [PMID: 34276360 DOI: 10.3389/fphar.2021.656115] [Reference Citation Analysis]
7 Li W, Deng M, Gong J, Zhang X, Ge S, Zhao L. Sodium Acetate Inhibit TGF-β1-Induced Activation of Hepatic Stellate Cells by Restoring AMPK or c-Jun Signaling. Front Nutr 2021;8:729583. [PMID: 34660662 DOI: 10.3389/fnut.2021.729583] [Reference Citation Analysis]
8 Han X, Ding C, Sang X, Peng M, Yang Q, Ning Y, Lv Q, Shan Q, Hao M, Wang K, Wu X, Zhang H, Cao G. Targeting Sirtuin1 to treat aging-related tissue fibrosis: From prevention to therapy. Pharmacol Ther 2021;:107983. [PMID: 34480962 DOI: 10.1016/j.pharmthera.2021.107983] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Chen Q, Bao L, Lv L, Xie F, Zhou X, Zhang H, Zhang G. Schisandrin B regulates macrophage polarization and alleviates liver fibrosis via activation of PPARγ. Ann Transl Med 2021;9:1500. [PMID: 34805362 DOI: 10.21037/atm-21-4602] [Reference Citation Analysis]